Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:31:36.096Z.
Consensus retrieved: 2026-10-06T12:20:07.713Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:31:36.096Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6
FORWARD PE RATIO
N/A
Helus Pharma Inc.
Market Cap
$666.95M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Helus Pharma Inc. (HELP) | $666.95M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | N/A |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-03-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
